Supriya Lifescience Limited — Updates, 17-12-2024: Press Release

Supriya Lifescience Ltd has inaugurated its new multipurpose Active Pharmaceutical Ingredients (API) production block, Module E, at the Lote Parshuram site. This facility represents an investment of approximately ₹125 crore and enhances production capacity by 335 kiloliters, increasing total capacity from 597 KLPD to 932 KLPD.

This expansion is aligned with SLL's strategic focus on boosting R&D capabilities and ramping up the commercialization of innovative products in niche therapeutic areas. The facility spans 5,000 square meters and features 33 reactors with diverse capacities, designed to ensure efficient and safe operations while adhering to the latest quality standards.

Dr. Satish Wagh, Executive Chairman, stated that the new module aims to enhance product quality and efficiency, support backward integration, and reduce reliance on imports. With this development, SLL reinforces its commitment to innovation and sustainability, positioning itself for future growth and value creation for stakeholders. Positive outlook for the company as it strengthens its infrastructure and expands its product portfolio.